WVP
CAPR icon

Worth Venture Partners’s Capricor Therapeutics CAPR Stock Holding History

Worth Venture Partners’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,345
Closed -$155K – 42
2025
Q1 		$155K Buy
+16,345
New +$227K 0.29% 32

Other funds holding CAPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $606M AUM 63.41% 1-Year Est. Return
BDF
Black Diamond Financial Towson, Maryland $916M AUM 15.95% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Worth Venture Partners's CAPR Position: Q2 2025 in Review

Worth Venture Partners sold out of Capricor Therapeutics (CAPR) in Q2 2025, closing a stake of 16,345 shares — an estimated $155K sold.

Worth Venture Partners first reported a position in CAPR in Q1 2025 and held it in 1 quarter. The position peaked at $155K in Q1 2025. 107 funds tracked by Wall St. Rank hold CAPR as of Q2 2025.

  • Worth Venture Partners reported no remaining Capricor Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Worth Venture Partners sold 16,345 Capricor Therapeutics shares in Q2 2025, an estimated $155K.
  • Worth Venture Partners first reported a position in Capricor Therapeutics in Q1 2025 and held it in 1 quarter.
  • Worth Venture Partners's Capricor Therapeutics position peaked at $155K in Q1 2025.
  • 107 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2025.

Based on Worth Venture Partners's 13F filing for Q2 2025, filed 13 Aug 2025.